ClinicalTrials.gg
Active, not recruitingNCT07409259Updated Feb 13, 2026

PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure

An Early Phase 1 interventional study of exosome injection and standard comprehensive internal medical treatment, in Acute-on-Chronic Liver Failure (ACLF), sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University — 6 open to participants now, 8 under way, none of them phase 3. Acute-On-Chronic Liver Failure · Third Affiliated Hospital, Sun Yat-Sen University.

Planned enrollment
7th of 11
20 · median 60
Started
2026
with 1 other
Phase 1
3 of 13
none open now
Registered
12th of 13
by date

Among the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 1, and was the 12th registered.

Acute-On-Chronic Liver Failure

167 studies on the registry are indexed under Acute-On-Chronic Liver Failure; 61 are open to participants now.

Browse Acute-On-Chronic Liver Failure studies →

Open to participants now

6 of the 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 32 Acute-On-Chronic Liver Failure studies recruiting now, 11 (34%) set no upper age limit and 15 (47%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Acute-On-Chronic Liver Failure by Third Affiliated Hospital, Sun Yat-Sen University, or all of them as a file.
02

Study summary

The goal of this single-center, prospective, randomized controlled study is to evaluate the safety and efficacy of PT-MSCs Exosome Injection (code: PT-MSCs-EVS-2023-1) in treating patients with acute-on-chronic liver failure (ACLF). As an exploratory study with a small sample size, the primary focus is to observe safety outcomes and preliminary efficacy. The study will enroll patients aged 18 to 65 years who meet the diagnostic criteria for acute-on-chronic liver failure as outlined in the 2024 Chinese Liver Failure Clinical Guidelines and have a COSSH-ACLF II score of less than 7.4.

The main questions this study aims to answer are:

Does the combined therapy improve the 12-week survival rate compared to standard treatment alone? What is the safety profile of the PT-MSCs Exosome Injection (incidence of adverse events and serious adverse events)? Does the treatment improve clinical symptoms (such as fatigue, anorexia, and jaundice) and biochemical markers (liver function, coagulation, inflammation)? Does the treatment improve the 4-week survival rate and reduce the incidence of adverse outcomes (death, treatment abandonment, or liver transplantation)?

Participants will be recruited and screened to ensure eligibility. A total of 20 eligible participants will be randomly allocated into one of two groups in a 1:1 ratio using block randomization:

Control Group (10 patients): Participants will receive standard comprehensive internal medical treatment, including antiviral therapy, hepatoprotective drugs, and symptomatic support. Artificial liver support or liver transplantation may be performed based on the investigator's clinical judgment.

Study Group (10 patients): In addition to the standard treatment received by the control group, participants will receive PT-MSCs Exosomes (2×10\^11 particles per dose).

For the Study Group, the exosome injection is diluted in 100 mL of normal saline and administered via intravenous infusion over a period of not less than 2 hours. Treatment is administered once every 3 days (on Day 1, Day 4, Day 7, and Day 10) for a total of 4 doses. All participants will undergo follow-up assessments at specific intervals (Days 4, 7, 10, 13, 28, and 84) to monitor survival, clinical improvement, and safety signals.

03

Conditions studied

  • Acute-on-Chronic Liver Failure (ACLF)

Keywords

  • Acute -On-Chronic Liver Failure
  • Bio-artificial liver
  • Exosome
  • Mesenchymal stem cells
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 65 years, regardless of gender.
  • Diagnosed with Acute-on-Chronic Liver Failure (ACLF) according to the diagnostic criteria in the "Guidelines for Diagnosis and Treatment of Liver Failure (2024 Edition)."
  • COSSH-ACLF II score \< 7.4.
  • Participants must be fully informed about the study and voluntarily sign a written form prior to participation.

Exclusion criteria

Exclusion Criteria:

  • Patients with chronic liver failure.
  • Patients with active bleeding or Disseminated Intravascular Coagulation (DIC) that has not been effectively controlled.
  • Known allergy to blood products or any medications/drugs used in the treatment protocol.
  • Patients with circulatory failure.
  • History of myocardial infarction, cerebral infarction, or cerebral hemorrhage within the past 6 months.
  • History of within the past 5 years (excluding cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).
  • Pregnant or lactating women.
  • Any other conditions that, in the opinion of the investigator, make the patient unsuitable for participation in the trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Control Group

    Participants will receive standard comprehensive internal medical treatment, including antiviral therapy, hepatoprotective drugs, and symptomatic support. Artificial liver support or liver transplantation may be performed based on the investigator's clinical judgment.

    Combination Product: standard comprehensive internal medical treatment,

  • Experimental
    Study Group

    In addition to the standard treatment received by the control group, participants will receive PT-MSCs Exosomes (2×10\^11 particles per dose).

    Biological: exosome injection · Combination Product: standard comprehensive internal medical treatment,

Interventions

  • Biologicalexosome injection

    For the Study Group, the exosome injection is diluted in 100 mL of normal saline and administered via intravenous infusion over a period of not less than 2 hours. Treatment is administered once every 3 days (on Day 1, Day 4, Day 7, and Day 10) for a total of 4 doses.

  • Combination productstandard comprehensive internal medical treatment,

    Participants will receive standard comprehensive internal medical treatment, including antiviral therapy, hepatoprotective drugs, and symptomatic support.

06

What researchers measure

Primary outcomes

  1. 12-Week Survival Rate

    The percentage of participants who are alive at 12 weeks after enrollment.

    Time frame: 12 weeks

Secondary outcomes

  1. Changes from the baseline in COSSH-ACLF II score

    The Chinese Severe Hepatitis B Study Group (COSSH), based on a multicenter, open-label large cohort study, has established a novel prognostic scoring system for hepatitis B virus (HBV)-ACLF: COSSH-ACLF II s. The COSSH-ACLF II score is calculated as: 1.649×ln(INR) + 0.457×HE grade + 0.425×ln(neutrophils) + 0.396×ln(TBil) + 0.576×ln(urea) + 0.033×age. Theoretically, the score ranges from \~1.0 to \~15.0, though clinically observed values typically fall between 4.5 and 10.0. A score of less than 7.4 indicates a low-risk group, a score between 7.4 and 8.4 indicates a moderate-risk group, and a score greater than 8.4 indicates a high risk of 28- and 90-day mortality.Higher scores indicate greater severity of liver failure and a worse outcome.

    Time frame: 12 weeks

  2. Changes from the baseline in Child-Pugh score

    The Child-Pugh Score assesses the prognosis of chronic liver disease based on five indicators: hepatic encephalopathy, ascites, total bilirubin, albumin, and PT/INR. The total score ranges from 5 to 15. Higher scores indicate worse liver function. (Classification: Grade A = 5-6 points; Grade B = 7-9 points; Grade C = 10-15 points.)

    Time frame: 12-weeks

  3. Change from Baseline in Clinical Symptom Score

    Assessment of clinical symptoms including fatigue, anorexia, nausea, jaundice, and level of consciousness. Each symptom is graded on a scale from 0 (absent) to 3(severe). The individual scores are summed to calculate a total symptom score ranging from 0 to 15. Higher scores indicate more severe symptoms.

    Time frame: 12 weeks

  4. 4-Week Survival Rate

    The percentage of participants who are alive at 4 weeks after enrollment

    Time frame: 4 weeks

  5. The rate of participants with adverse outcomes at Week 4 and Week 12

    The rate of adverse outcomes, defined as death, treatment abandonment, or liver transplantation.

    Time frame: 4-week , 12-week

Other outcomes

  1. Change from Baseline in Hemoglobin

    Assessment of hemoglobin concentration. Presented in units of g/L.

    Time frame: Day1, Day4、Day7、Day10、Day13、Day28、Day84

  2. Change from Baseline in International Normalized Ratio (INR)

    Assessment of coagulation function via INR. INR is a standardized ratio without units. Higher values indicate worse coagulation function.

    Time frame: Day1, Day4、Day7、Day10、Day13、Day28、Day84

  3. Change from Baseline in Interleukin-6 (IL-6)

    Measurement of serum Interleukin-6 concentration to evaluate the pro-inflammatory cytokine response. Presented in units of pg/mL.

    Time frame: Day1, Day4、Day7、Day10、Day13、Day28、Day84

  4. Change from Baseline in White Blood Cell (WBC) Count

    Assessment of inflammation through total white blood cell count. Presented in units of 10\^9/L.

    Time frame: Day1, Day4、Day7、Day10、Day13、Day28、Day84

  5. Number of participants with treatment-related adverse Events (AEs) and serious Adverse Events (SAEs)

    Safety assessment evaluating the frequency and severity of adverse events throughout the study duration. All treatment-related adverse events will be assessed by CTCAE v5.0.

    Time frame: 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Feb 13, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07409259
Responsible party
Liang Peng (Professor, Third Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
Feb 13, 2026
Start date
Jan 1, 2026
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Feb 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion